These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 17465065)

  • 1. [Pleiotropic effects of tissue plasminogen activator].
    Itoh Y
    Nihon Rinsho; 2006 Oct; 64 Suppl 7():589-96. PubMed ID: 17465065
    [No Abstract]   [Full Text] [Related]  

  • 2. Administration of recombinant tissue plasminogen activator to a case of cerebral infarction in the setting of painless aortic dissection.
    Takeuchi S; Takasato Y; Masaoka H; Otani N
    Neurol India; 2009; 57(6):808-9. PubMed ID: 20139520
    [No Abstract]   [Full Text] [Related]  

  • 3. [T-PA].
    Takada T; Minematsu K
    Nihon Rinsho; 2006 Oct; 64 Suppl 7():585-8. PubMed ID: 17461210
    [No Abstract]   [Full Text] [Related]  

  • 4. [Thrombolytic treatment in acute brain infarction].
    Davalos A
    Neurologia; 2004 May; 19(4):143-5. PubMed ID: 15131732
    [No Abstract]   [Full Text] [Related]  

  • 5. [Fibrinolytic therapy in ischemic brain infarct].
    Del Zoppo GJ; Hacke W
    Dtsch Med Wochenschr; 1987 Apr; 112(15):603-8. PubMed ID: 3104001
    [No Abstract]   [Full Text] [Related]  

  • 6. [Quick diagnostic neuroimaging for acute cerebral infarction and decision-making on thrombolytic therapy].
    Nakagawara J
    Nihon Rinsho; 2006 Nov; 64 Suppl 8():25-8. PubMed ID: 17471624
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cerebral infarction--thrombolytic therapy by tissue-type plasminogen activator or prourokinase].
    Amano T
    Nihon Rinsho; 1989 Apr; 47(4):917-20. PubMed ID: 2501542
    [No Abstract]   [Full Text] [Related]  

  • 8. [Thrombolytic therapy in acute ischemic stroke: present and future].
    Mori E
    No Shinkei Geka; 2003 Mar; 31(3):249-60. PubMed ID: 12684978
    [No Abstract]   [Full Text] [Related]  

  • 9. [Intravenous tissue plasminogen activator in the treatment of acute ischemic stroke: feasibility, safety, and efficiency in the 2 first years of the clinical practice].
    Feuerhake W; Chamorro H; Araya F
    Rev Med Chil; 1999 Jul; 127(7):814-9. PubMed ID: 10668289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thrombolytic therapy of cerebral infarction using alteplase--the Helsinki model].
    Lindsberg PJ; Soinne L; Roine RO; Salonen O; Tatlisumak T; Kallela M; Häppölä O; Tiainen M; Haapaniemi E; Kuisma M; Kaste M
    Duodecim; 2003; 119(18):1723-9. PubMed ID: 14587458
    [No Abstract]   [Full Text] [Related]  

  • 11. Tissue-type plasminogen activator: a new fibrinolytic agent.
    Milligan KS
    Heart Lung; 1987 Jan; 16(1):69-74. PubMed ID: 3098703
    [No Abstract]   [Full Text] [Related]  

  • 12. Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase.
    Jin L; Jin H; Zhang G; Xu G
    Clin Hemorheol Microcirc; 2000; 23(2-4):213-8. PubMed ID: 11321442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Relationship Between Peripheral Red Cell Distribution Width and Acute Cerebral Infarction in Patients with rtPA Thrombolysis.
    Cong L; Gao H; Ma W
    Neurotox Res; 2020 Jun; 38(1):211-218. PubMed ID: 32162280
    [No Abstract]   [Full Text] [Related]  

  • 14. Thrombolytic agents for acute evolving myocardial infarction: comparative effects.
    Sherry S
    Ration Drug Ther; 1987 Jan; 21(1):1-9. PubMed ID: 3112866
    [No Abstract]   [Full Text] [Related]  

  • 15. Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator.
    Juhan-Vague I; Stassen JM; Alessi MC; Elias A; Aillaud MF; Serradimigni A; Collen D
    Semin Thromb Hemost; 1989 Oct; 15(4):390-4. PubMed ID: 2554499
    [No Abstract]   [Full Text] [Related]  

  • 16. Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy.
    Winkler DT; Biedermann L; Tolnay M; Allegrini PR; Staufenbiel M; Wiessner C; Jucker M
    Ann Neurol; 2002 Jun; 51(6):790-3. PubMed ID: 12112090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction].
    Czyrski J
    Wiad Lek; 1989 Apr; 42(7):450-2. PubMed ID: 2516932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke.
    Cocho D; Belvís R; Martí-Fàbregas J; Molina-Porcel L; Díaz-Manera J; Aleu A; Pagonabarraga J; García-Bargo D; Mauri A; Martí-Vilalta JL
    Neurology; 2005 Feb; 64(4):719-20. PubMed ID: 15728300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-plasminogen activator: a new drug in reperfusion therapy (continuing education credit).
    Strauss E; Rudy EB
    Crit Care Nurse; 1986; 6(3):30-5, 38-43. PubMed ID: 3089687
    [No Abstract]   [Full Text] [Related]  

  • 20. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.